NCT02482168View on ClinicalTrials.gov

Study of the CD40 Agonistic Monoclonal Antibody APX005M

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 13, 2018

Study Completion Date

June 19, 2018

Conditions
CancerNSCLCMelanomaUrothelial CarcinomaMSI-HHead and Neck Cancer
Interventions
DRUG

APX005M

APX005M is a CD40 agonistic monoclonal antibody

Trial Locations (3)

19104

Abramson Cancer Center of The University of Pennsylvania, Philadelphia

44106

Case Western Reserve University, Cleveland

91010

City of Hope, Duarte

All Listed Sponsors
lead

Apexigen America, Inc.

INDUSTRY

NCT02482168 - Study of the CD40 Agonistic Monoclonal Antibody APX005M | Biotech Hunter | Biotech Hunter